David H. Henry, M.D.
Clinical Professor of Medicine (Hematology-Oncology)
Department: Medicine
Contact information
Penn Hematology/Oncology
Abramson Cancer Center
Pennsylvania Hospital, Farm Journal Building
230 West Washington Square
Philadelphia, PA 19106
Abramson Cancer Center
Pennsylvania Hospital, Farm Journal Building
230 West Washington Square
Philadelphia, PA 19106
Office: 215-829-6088
Fax: 215-829-6104
Fax: 215-829-6104
Email:
david.henry@uphs.upenn.edu
david.henry@uphs.upenn.edu
Education:
B.A.
Princeton University, 1970.
M.D.
University of Pennsylvania School of Medicine, 1975.
Permanent linkB.A.
Princeton University, 1970.
M.D.
University of Pennsylvania School of Medicine, 1975.
Selected Publications
Paul G Rubinstein, MD, Page C Moore, PhD, Milan Bimali, PhD, Jeanette Y Lee, PhD, Michelle A Rudek, PhD, Amy Chadburn, MD, Lee Ratner, MD, David H Henry, MD, Ethel Cesarman, MD, Camille E DeMarco, MPH, Dominique Costagliola, PhD, Yassine Taoufik, PhD, Juan Carlos Ramos, MD, Elad Sharon, MD, Erin G Reid, MD, Richard F Ambinder, MD, Ronald Mitsuyasu, MD, Nicolas Mounier, MD, Caroline Besson, MD, Ariela Noy, MD for the AIDS Malignancy Consortium and the Lymphoma Study Association † : Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet 10(8): E624-E632, August 2023.David Henry: A Commentary On: Neoadjuvant Chemoradiation for Treatment of LARC. Practice Update June 2023.
David Henry: A commentary on: Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer. Practice Update June 2023.
David Henry: A Commentary On: Adjuvant Osimertinib for Resected EFGR-Mutated Stage Ib-IIIA NSCLC. Practice Update June 2023.
David Henry: A commentary on: Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma. Practice Update June 2023.
John A. Glaspy, Nashat Y Gabrail, Patricia A. Locantore-Ford, Gopal C Saha, Elise Hardy, Tyson Lee, Katharina Modelska, David H. Henry: Open‐label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non‐myeloid malignancies. Journal of Clinical Oncology January 2023.
David Henry: 2022 Top Story in Oncology: Durvalumab Plus Gemcitabine and Cisplatin as First-Line Treatment for Advanced Biliary Tract Cancer. Practice update December 2022.
David Henry: A commentary on: ASCO 2022: Abstract Recommendations. Practice Update June 2022.
Henry, DH., Maki RG: Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clin Canc Res 28(12): 2485-2487, Jun 13 2022.
Hajizadeh Barfejani, A; Prasad, S; Henry, D.: SAFE ADMINISTRATION OF SECOND DOSE OF MRNA COVID-19 VACCINE FOLLOWING DEVELOPMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA. HemaSphere 6: 2093-2194, June 2022 Notes: DOI: 10.1097/01.HS9.0000852120.42895.8a.